Go Pro
Justin Walsh

Justin Walsh Analyst Performance

Director, Healthcare at JonesTrading

Justin Walsh is a stock analyst at JonesTrading in the healthcare sector, covering 12 publicly traded companies. Over the past year, Justin Walsh has issued 15 stock ratings, including buy and hold recommendations. While full access to Justin Walsh's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Justin Walsh's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
22 Last 1 Years
Buy Recommendations
71.43% 15 Buy Ratings
Companies Covered
12 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy4.8%1 ratings
Buy66.7%14 ratings
Hold28.6%6 ratings
Sell0.0%0 ratings

Out of 21 total stock ratings issued by Justin Walsh at JonesTrading, the majority (66.7%) have been Buy recommendations, followed by 28.6% Hold and 4.8% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
83.3% of companies on NASDAQ
10 companies
NYSE
8.3% of companies on NYSE
1 company
NYSEAMERICAN
8.3% of companies on NYSEAMERICAN
1 company

Justin Walsh, an analyst at JonesTrading, currently covers 12 companies listed on NASDAQ, NYSE and NYSEAMERICAN, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
12 companies
100.0%

Justin Walsh of JonesTrading specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
PHARMACEUTICALS
6 companies
50.0%
BIOTECHNOLOGY
5 companies
41.7%
HEALTHCARE EQUIPMENT & SUPPLIES
1 company
8.3%

About Justin Walsh

Justin Walsh PhD covers biotechnology companies within the Healthcare sector. Before joining JonesTrading, Dr. Walsh was a Research Analyst at B. Riley Securities covering SMID cap biotechnology and healthcare companies with a primary focus on oncology. Earlier, he contributed to the coverage of a diverse set of biotechnology companies as an equity research associate at JMP Securities and Raymond James & Associates. He earned his PhD in chemistry from Hunter College and the City University of New York Graduate Center, wherein he collaborated with Memorial Sloan Kettering Cancer Center to study next-generation cancer imaging approaches. He holds a BA in chemistry and mathematics from Rollins College.
Follow on LinkedIn

Justin Walsh's Ratings History at JonesTrading

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Seaport Therapeutics, Inc. stock logo
SPTX
Seaport Therapeutics
8/26/2026Initiated Coverage$25.07$32.00Buy
Seaport Therapeutics, Inc. stock logo
SPTX
Seaport Therapeutics
8/25/2026Set Price Target$24.83$32.00
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
8/17/2026Downgrade$100.68Hold
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
8/13/2026Boost Price Target$44.13$90.00Buy
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
7/29/2026Reiterated Rating$100.16Buy
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
7/17/2026Downgrade$7.15Hold
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
7/9/2026Boost Price Target$107.60$129.00Buy
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
6/24/2026Boost Price Target$42.80$74.00Buy
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
4/2/2026Lower Price Target$22.47$44.00Buy
NeuroOne Medical Technologies Corporation stock logo
NMTC
NeuroOne Medical Technologies
3/2/2026Initiated Coverage$4.02$9.00Buy
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
2/27/2026Downgrade$75.43Hold
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
12/23/2025Initiated Coverage$13.30$61.00Buy
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
12/23/2025Initiated Coverage$4.30$16.00Buy
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
9/18/2025Initiated Coverage$44.03$83.00Buy
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
9/16/2025Lower Price Target$51.49$84.00Buy
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
8/5/2025Downgrade$8.52Hold
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
6/23/2025Lower Price Target$80.26$109.00Buy
VolitionRX Limited stock logo
VNRX
VolitionRX
6/10/2025Upgrade$11.13$60.00Strong-Buy
Clene Inc. stock logo
CLNN
Clene
4/23/2025Initiated Coverage$2.98$30.00Buy
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
4/2/2025Reiterated Rating$33.43Hold
BioLineRx Ltd. stock logo
BLRX
BioLineRx
4/2/2025Reiterated Rating$2.92Hold
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
3/21/2025Lower Price Target$98.85$122.00Buy